Welcome to our dedicated page for Oncocyte news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte stock.
Oncocyte Corporation develops molecular diagnostic technologies focused on solid organ transplant monitoring and oncology. Company news centers on its blood-based transplant rejection assays, including GraftAssure research-use-only kits, VitaGraft clinical monitoring tests, and the GraftAssureCore lab-developed test, along with reimbursement updates, clinical publications, and development of regulated kitted products for transplant centers.
Updates also cover quarterly results, pharma services activity from its laboratory operations, strategic relationships such as Bio-Rad, capital actions, investor conference participation, and oncology assays such as DetermaIO and DetermaCNI.
Oncocyte Corporation (Nasdaq: OCX) announced the release of its first quarter 2022 financial results on May 11, 2022. The company will host a conference call and webcast that day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent highlights. Oncocyte focuses on precision diagnostics, offering tests like DetermaRx™ and DetermaIO™ to enhance cancer treatment decision-making and improve patient outcomes. The replay of the conference will be available on the company's website post-call.
Oncocyte Corporation (Nasdaq: OCX) announced plans to present new clinical research data on DetermaIO™ at the ASCO Annual Meeting scheduled for June 3-7, 2022. The research evaluates the 27-gene IO score for predicting responses to immune checkpoint therapies in patients with metastatic colorectal, gastric, and breast cancers. Three abstracts will be presented throughout the meeting, highlighting the potential of DetermaIO in personalizing cancer treatments. The company will also support a CME event discussing advancements in molecular diagnostics.
Oncocyte Corporation (Nasdaq: OCX) announced a public offering of 26,266,417 shares of its common stock priced at $1.3325 each, along with warrants for 13,133,208.5 shares, expected to raise approximately $35 million before expenses. The offering is set to close by April 19, 2022. Funds will support commercialization of DetermaRx™, DetermaIO™, and TheraSure™, as well as collaboration with Life Technologies Corporation for regulatory approval of their tests. The underwriters have a 30-day option for additional shares to cover over-allotments.
Oncocyte Corporation (Nasdaq: OCX) has initiated an underwritten public offering of common stock and warrants, with plans to grant underwriters a 30-day option for an additional 15% of shares. The offering's completion is subject to market conditions. Proceeds will primarily support the commercialization of DetermaRx™, the development of DetermaIO™ and TheraSure™, and other tests in its pipeline, alongside costs from a collaboration with Life Technologies Corporation. A shelf registration statement was previously declared effective in June 2021.
Oncocyte Corporation (Nasdaq: OCX) announced a registered direct offering of 11,765 shares of Series A Convertible Preferred Stock, convertible into 7,689,542 shares of common stock at $1.53 per share. The offering aims to raise approximately $10 million in gross proceeds to enhance commercialization of DetermaRx™, DetermaIO™, and TheraSure™, among others. The Preferred Stock carries a 6% annual dividend and requires redemption by April 8, 2024 if not converted. There is no public trading market for the Preferred Stock.
Oncocyte Corporation (Nasdaq: OCX) announced findings from a real-world cohort study demonstrating that its DetermaIO test can effectively predict responses to immunotherapy in patients with bladder cancer. The study validated the test's capacity to identify responders to immune checkpoint inhibitors (ICIs) and confirmed previous results from the IMvigor210 trial. DetermaIO, launched in Q4 2021, assesses the tumor microenvironment, providing critical insights that could improve patient treatment decisions and outcomes. The findings were presented at the AACR Annual Meeting 2022.
Oncocyte Corporation (Nasdaq: OCX) announced it will present new data on its DetermaIO™ test at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The 27-gene expression test helps identify patients with bladder cancer who are likely to respond to immune checkpoint inhibitors (ICIs). This new analysis confirms previous findings linking the IO Score to responses to Genentech’s Tecentriq® therapy. DetermaIO is the first test to evaluate the entire tumor microenvironment, enhancing therapeutic decision-making for patients undergoing immunotherapy.
Oncocyte Corporation (Nasdaq: OCX) reported significant growth in its Q4 2021 results, with revenues up 104% year-over-year to $3.6 million and test volume increasing 54%. The company announced a strategic partnership with Thermo Fisher Scientific for distributed in vitro diagnostic assays. Notably, their DetermaCNI blood monitoring test has shown promising results for detecting cancer recurrence, and they are on track to launch the TheraSure Transplant Monitor in March 2022. Despite growing revenues, operating losses widened to $35.7 million in Q4 2021.
Oncocyte Corporation (Nasdaq: OCX) has announced the release of its financial and operating results for the fourth quarter and year ending December 31, 2021, set for March 10, 2022, post U.S. market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate developments. Oncocyte specializes in precision diagnostics for cancer treatment, offering tests like DetermaRx™ and DetermaIO™ that aid in the diagnosis and monitoring of cancer. The company aims to enhance patient outcomes through its innovative diagnostics solutions.
Oncocyte Corporation (Nasdaq: OCX) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will present during a fireside chat on February 15, 2022, at 4:30 PM EST. The conference aims to enhance patient outcomes through personalized diagnostic insights. Notably, Oncocyte offers proprietary tests like DetermaRx™ and DetermaIO™ to assist in cancer diagnosis and treatment. Investors can reach out to BTIG representatives for meeting opportunities, though the presentation won't be webcast.